Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $81.15 Consensus Target Price from Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have earned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $81.1538.

Several equities research analysts recently commented on VERA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group restated a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Raymond James Financial reaffirmed a “strong-buy” rating and set a $84.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, August 11th. Finally, Wedbush reiterated a “neutral” rating and issued a $34.00 price objective on shares of Vera Therapeutics in a research note on Monday, August 17th.

Vera Therapeutics Stock Performance

Shares of VERA opened at $32.28 on Wednesday. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $2.33 billion, a P/E ratio of -5.51 and a beta of 0.92. The firm’s fifty day simple moving average is $36.32 and its two-hundred day simple moving average is $38.04. Vera Therapeutics has a 12 month low of $21.15 and a 12 month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period last year, the company earned ($1.20) EPS. As a group, analysts predict that Vera Therapeutics will post -6.43 EPS for the current year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the completion of the sale, the chief executive officer directly owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VERA. Optimize Financial Inc grew its stake in shares of Vera Therapeutics by 1.5% in the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares during the period. Virtus Investment Advisers LLC raised its stake in Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after buying an additional 290 shares during the period. Intech Investment Management LLC boosted its holdings in Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after acquiring an additional 424 shares in the last quarter. Invesco Ltd. boosted its holdings in Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after acquiring an additional 550 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after acquiring an additional 639 shares during the period. Institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.